{"id":80066,"date":"2026-05-11T22:27:15","date_gmt":"2026-05-11T22:27:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/80066\/"},"modified":"2026-05-11T22:27:15","modified_gmt":"2026-05-11T22:27:15","slug":"hims-hers-raises-2026-revenue-forecast-on-strong-demand-for-personalized-care","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/80066\/","title":{"rendered":"Hims &#038; Hers raises 2026 revenue forecast on strong demand for personalized care"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\">May 11 (Reuters) &#8211; Hims &amp; Hers Health raised its 2026 revenue \u200cforecast on Monday, betting \u200con increased sales for its personalized healthcare \u200bofferings.<\/p>\n<p class=\"yf-1fy9kyt\">The company now expects annual revenue between $2.8 billion and $3 billion, compared with its previous forecast of $2.7 \u200cbillion to $2.9 \u2060billion.<\/p>\n<p class=\"yf-1fy9kyt\">In March, Hims said it would partner with \u2060Novo Nordisk to offer its blockbuster weight-loss drug, Wegovy, on \u200bits platform, \u200bending a \u200blegal dispute between \u200cthe companies.<\/p>\n<p class=\"yf-1fy9kyt\">The dispute had followed Hims&#8217; launch of a low-cost compounded alternative to Wegovy, which it has since discontinued.<\/p>\n<p class=\"yf-1fy9kyt\">Hims expects second-quarter \u200crevenue in the \u200brange of $680 million to $700 \u200bmillion, \u200bcompared with analysts&#8217; average \u200cestimate of $642.95 million, according \u200bto data \u200bcompiled by LSEG.<\/p>\n<p class=\"yf-1fy9kyt\">Shares of the company were down 6% \u200bat $27.20 in \u200cafter-market trading.<\/p>\n<p class=\"yf-1fy9kyt\">(Reporting by Siddhi Mahatole \u200band Amina Niasse; Editing \u200bby Shinjini Ganguli)<\/p>\n","protected":false},"excerpt":{"rendered":"May 11 (Reuters) &#8211; Hims &amp; Hers Health raised its 2026 revenue \u200cforecast on Monday, betting \u200con increased&hellip;\n","protected":false},"author":2,"featured_media":80067,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[42649,269,621,42648,272,42650],"class_list":["post-80066","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-annual-revenue","tag-forecast","tag-hims","tag-increased-sales","tag-novo-nordisk","tag-personalized-healthcare"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116558302204224891","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=80066"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80066\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/80067"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=80066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=80066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=80066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}